334 related articles for article (PubMed ID: 19773256)
1. Anti-CD20 monoclonal antibodies: historical and future perspectives.
Lim SH; Beers SA; French RR; Johnson PW; Glennie MJ; Cragg MS
Haematologica; 2010 Jan; 95(1):135-43. PubMed ID: 19773256
[TBL] [Abstract][Full Text] [Related]
2. T-cell infiltrate after monoclonal anti-CD20 antibody therapy for B-cell lymphoma.
Vincent-Salomon A; Mathiot C; Macintyre E; Girre V; Fourquet A; Mercier C; Fréneaux P; Dumont J; Decaudin D
Leuk Lymphoma; 2000 Apr; 37(3-4):387-91. PubMed ID: 10752990
[No Abstract] [Full Text] [Related]
3. Correspondence re: T. Davis et al., therapy of B-cell lymphoma with anti-CD20 antibodies can result in loss of CD20 antigen expression. Clin. Cancer Res., 5: 611-615, 1999.
Grillo-López AJ; Kunkel L
Clin Cancer Res; 2000 Jan; 6(1):317-8. PubMed ID: 10656464
[No Abstract] [Full Text] [Related]
4. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
[TBL] [Abstract][Full Text] [Related]
5. Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas.
Funakoshi S; Longo DL; Murphy WJ
J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):93-101. PubMed ID: 8732692
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD20 monoclonal antibodies: beyond B-cells.
Avivi I; Stroopinsky D; Katz T
Blood Rev; 2013 Sep; 27(5):217-23. PubMed ID: 23953071
[TBL] [Abstract][Full Text] [Related]
7. CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy.
Massengale WT; McBurney E; Gurtler J
J Am Acad Dermatol; 2002 Mar; 46(3):441-3. PubMed ID: 11862185
[TBL] [Abstract][Full Text] [Related]
8. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma.
Anderson DR; Grillo-López A; Varns C; Chambers KS; Hanna N
Biochem Soc Trans; 1997 May; 25(2):705-8. PubMed ID: 9191187
[No Abstract] [Full Text] [Related]
9. [Monoclonal anti-CD20 antibody therapy].
Juhel L; Solal-Celigny P
Rev Prat; 2004 Apr; 54(7):711-2. PubMed ID: 15253285
[No Abstract] [Full Text] [Related]
10. Loss of CD20 expression in relapsed lymphomas after rituximab therapy.
Haidar JH; Shamseddine A; Salem Z; Mrad YA; Nasr MR; Zaatari G; Bazarbachi A
Eur J Haematol; 2003 May; 70(5):330-2. PubMed ID: 12694172
[TBL] [Abstract][Full Text] [Related]
11. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.
Davis TA; Czerwinski DK; Levy R
Clin Cancer Res; 1999 Mar; 5(3):611-5. PubMed ID: 10100713
[TBL] [Abstract][Full Text] [Related]
12. Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma.
Roguedas AM; Watier H; Paintaud G; de Muret A; Vaillant L; Machet L
Br J Dermatol; 2005 Mar; 152(3):541-4. PubMed ID: 15787825
[TBL] [Abstract][Full Text] [Related]
13. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells.
Shan D; Ledbetter JA; Press OW
Cancer Immunol Immunother; 2000 Mar; 48(12):673-83. PubMed ID: 10752475
[TBL] [Abstract][Full Text] [Related]
14. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.
Mössner E; Brünker P; Moser S; Püntener U; Schmidt C; Herter S; Grau R; Gerdes C; Nopora A; van Puijenbroek E; Ferrara C; Sondermann P; Jäger C; Strein P; Fertig G; Friess T; Schüll C; Bauer S; Dal Porto J; Del Nagro C; Dabbagh K; Dyer MJ; Poppema S; Klein C; Umaña P
Blood; 2010 Jun; 115(22):4393-402. PubMed ID: 20194898
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo purging of B lymphoma cells from stem-cell products using anti-CD20 Abs.
Derigs HG
Cytotherapy; 2000; 2(6):445-53. PubMed ID: 12044225
[TBL] [Abstract][Full Text] [Related]
16. Combating non-Hodgkin lymphoma by targeting both CD20 and HLA-DR through CD20-243 CrossMab.
Zhao L; Xie F; Tong X; Li H; Chen Y; Qian W; Duan S; Zheng J; Zhao Z; Li B; Zhang D; Zhao J; Dai J; Wang H; Hou S; Guo Y
MAbs; 2014; 6(3):740-8. PubMed ID: 24670986
[TBL] [Abstract][Full Text] [Related]
17. The Central Role for Microenvironment in B-Cell Malignancies: Recent Insights into Synergistic Effects of its Therapeutic Targeting and Anti-CD20 Antibodies.
Ahmadzadeh V; Tofigh R; Farajnia S; Pouladi N
Int Rev Immunol; 2016; 35(2):136-55. PubMed ID: 26325124
[TBL] [Abstract][Full Text] [Related]
18. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines.
Cardarelli PM; Quinn M; Buckman D; Fang Y; Colcher D; King DJ; Bebbington C; Yarranton G
Cancer Immunol Immunother; 2002 Mar; 51(1):15-24. PubMed ID: 11845256
[TBL] [Abstract][Full Text] [Related]
19. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.
Golay J; Zaffaroni L; Vaccari T; Lazzari M; Borleri GM; Bernasconi S; Tedesco F; Rambaldi A; Introna M
Blood; 2000 Jun; 95(12):3900-8. PubMed ID: 10845926
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of B-cell lymphoma with a chimeric anti-CD20 monoclonal antibody(rituximab)].
Tobinai K
Nihon Rinsho; 2002 Jan; 60(1):95-9. PubMed ID: 11808346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]